In:
Liver International, Wiley, Vol. 41, No. 2 ( 2021-02), p. 388-395
Kurzfassung:
This study aimed to evaluate the association between soluble TGF‐β (sTGF‐β) and soluble PD‐L1 (sPDL1), the dynamics of sTGF‐β during treatment and its prognostic role in biliary tract cancer (BTC). Methods The study population consisted of 90 BTC patients with first‐line chemotherapy (cohort 1) and 35 BTC patients with second‐ or third‐line chemotherapy (cohort 2). Plasma sTGF‐β and sPDL1 levels were measured using an enzyme‐linked immunosorbent assay. Results In both groups, sTGF‐β was positive correlated with sPDL1 for baseline and change values after treatment. sTGF‐β was elevated at disease progression compared to baseline in cohort 1 ( P 〈 .001). Increased sTGF‐β after treatment revealed worse DFS and OS ( P = .024, P = .028, respectively) in cohort 1 and significantly shorter OS ( P = .020) in cohort 2. In multivariable analysis, this prognostic value of increased sTGF‐β for OS retained its significance in both cohorts (Hazard ratio (HR) = 1.8, 95% CI, 1.1‐3.0, P = .028, in cohort 1; HR = 4.7, 95% CI, 1.5‐14.6, P = .007, in cohort 2). Conclusions In BTC, sTGF‐β was positively correlated with sPDL1 for baseline and changes after chemotherapy, and increased as tumour burden. sTGF‐β could be associated with survival; particularly, an elevated value after treatment suggests worse prognosis.
Materialart:
Online-Ressource
ISSN:
1478-3223
,
1478-3231
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2021
ZDB Id:
2124684-1
